Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must ...
After a chaotic year that has seen the attrition of over half the FDA’s senior leadership, many of these individuals have ...
The Commissioner’s National Priority Voucher awards companies that align with specific national priorities—such as boosting ...
CMS Administrator Mehmet Oz clarified that a deal has not yet been sealed with the manufacturer of semaglutide, Novo Nordisk, ...
Nabla and Takeda first joined hands in 2022, to push “the boundaries of next-generation biologics discovery,” according to ...
Under the terms of the deal, Gilead will put down $120 million in an upfront payment and will promise up to $1.52 billion in ...
Novo had around 250 employees working on cell therapies, all of whom will be laid off, though a spokesperson declined to ...
After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down ...
EMD Serono will offer its fertility treatments on TrumpRx at a steep discount, and Roche’s direct-to-consumer offering will ...
Veradermics is the second hair regrowth specialist to fundraise this week, after Pelage Pharmaceuticals announced Wednesday ...
The company is pursuing a Phase III trial for its topical stem cell-rejuvenating molecule that aims to reactivate hair growth ...
An unnamed source clarified that Sandra Retzky has not been fired from the FDA, but it remains unclear where she was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback